Evolving approaches for chronic hepatitis B： Differences and similarities between the 2025 American guidelines and the 2022 Chinese guidelines

This article provides a systematic comparative analysis of the key recommendations between the “AASLD/IDSA Practice Guidelines for the Treatment of Chronic Hepatitis B （2025 edition）” and the “Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis B （2022 edition）”. The comparison focuses on the following seven core domains： background and significance； methodology； prevention and screening strategies； treatment indications and indicators for treatment discontinuation； drug selection and therapeutic strategies； management of special populations； and liver cancer screening and management. By examining areas of consensus and divergence， this article highlights the differences and similarities in evidence-based approaches and clinical practice pathways between the two guidelines， in order to provide a reference for clinical decision-making concerning individualized diagnosis and treatment， as well as targeted management of hepatitis B patients in clinical practice.